Fundraising Fox
Graph AI
Pleasanton, US · Founded 2024 · 18 employees on LinkedIn · 2 known investors
Find your way into Graph AI
Each arrow is one introduction. Sign up to fill in the first one.
Ask Pradeepta Mishra to introduce you to Raghav Parvataraju
You →Pradeepta · together at LTIMindtree →Raghav
Sign up to find every way you can get introduced to Graph AI
- Your email: who you already know at Graph AI, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Graph AI team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Graph AI builds Graph Safety, an AI-native pharmacovigilance platform that takes on the operational load of patient safety work for pharmaceutical and biotech companies: intake and triage of adverse-event reports, end-to-end case processing, aggregate regulatory reporting and signal detection, with deterministic controls and audit trails so every output stays traceable to its source. Founded in 2024 in Pleasanton, California, by four enterprise-technology veterans, it raised a $3M seed from Bessemer Venture Partners in October 2025 and a $13.3M Series A led by Insight Partners in September 2026.
Also known as Graph AI Services, Inc. · Graphsafety · Graph · Graph Safety
Founders & leadership
Graph AI was founded in 2024 by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, Ashutosh Bordekar, and Raghavendra Parvataraju.
Investors · 2
Funding
SEC filings, press & company announcements$16.3M disclosed across 2 rounds · 2025–2026
- $13.3MSeries ASep 2026 · 3 sources
Insight Partners (lead), Bessemer Venture Partners
Source ↗ - $3MSeedOct 2025 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Sep 2026Graph AI builds Graph Safety, an AI-native pharmacovigilance platform that takes on the operational load of patient safety work for pharmaceutical and biotech companies: intake and triage of adverse-event reports, end-to-end case processing, aggregate regulatory reporting and signal detection, with deterministic controls and audit trails so every output stays traceable to its source. Founded in 2024 in Pleasanton, California, by four enterprise-technology veterans, it raised a $3M seed from Bessemer Venture Partners in October 2025 and a $13.3M Series A led by Insight Partners in September 2026.
Founding story
Four enterprise-technology veterans — Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala and Ashutosh Bordekar — founded Graph AI in 2024, first as an AI services firm working off their GraphX platform. A pharmaceutical customer whose 18-month engagement with legacy IT-services providers had failed pushed them to productise the work as software, and Graph Safety became the company's focus.
Traction
Customers in North America and other markets by September 2026; Bessemer's May 2026 case study reported enterprise customers monitoring more than 300 drugs. In live deployments case processing fell from over three hours to under ten minutes, with operating costs down by up to 66%.
Latest developments
Raised a $13.3M Series A led by Insight Partners with existing investor Bessemer Venture Partners on 10 September 2026, to expand across the US and Europe.
▸Full profile — market position, technology, go-to-market, ownership
Market position
Positions Graph Safety against services-heavy legacy pharmacovigilance stacks, where teams scaled to case volume by adding people around old systems; references the FDA's risk-based AI credibility framework, the EU AI Act and the CIOMS Working Group XIV report as the regulatory frame.
Technology
Graph Safety is built on the company's GraphX platform and ships as modules: /intake (capture and triage of adverse-event reports across channels), /nucleus (an AI safety database that processes cases end to end), /report (automated aggregate and E2B(R3) regulatory reporting, launched September 2026) and /signal (cross-case signal detection, in design partnership). AI output is wrapped in deterministic controls, validation layers and audit trails so source data and results stay traceable for inspections.
Go-to-market
Pharmacovigilance and patient-safety teams at pharmaceutical and biotechnology companies.
Ownership
Private; venture-backed (Bessemer Venture Partners, Insight Partners).
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 3
launches, deals, and filingsLed by Insight Partners with participation from existing investor Bessemer Venture Partners, to expand across the US and Europe.
$13.3M · closed source ↗
$3M · closed source ↗
Founded in 2024 by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala and Ashutosh Bordekar, initially as an AI services firm.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 7
primary sources listed
- Graph Safety — the first AI-native operating system for patient safetyGraph AI · company site
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Graph AI do?
- AI-native pharmacovigilance platform that automates adverse-event intake, case processing and regulatory reporting for pharma safety teams.
- Who founded Graph AI?
- Graph AI was founded by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, Ashutosh Bordekar, Raghavendra Parvataraju in 2024.
- Who are Graph AI's investors?
- Graph AI's investors include Bessemer Venture Partners, Insight Partners.
- How much funding has Graph AI raised?
- Graph AI has disclosed $16.3M raised across 2 rounds.
- Where is Graph AI headquartered?
- Graph AI is headquartered in Pleasanton, US.